再狭窄、支架血栓与出血并发症:在斯库拉与卡律布狄斯之间航行
该综述回顾了介入心脏病学40年发展,指出第一代药物洗脱支架降低再狭窄但增加晚期支架血栓,延长抗血栓治疗减少血栓却增加出血;第二代支架降低晚期血栓但永久性植入妨碍血管结构功能恢复,存在极晚期失败风险,当前需在支架血栓、再狭窄和出血间权衡。
要点
- 第一代药物洗脱支架降低再狭窄但增加晚期支架血栓风险。
- 延长抗血栓治疗减少支架血栓但增加出血风险。
- 第二代支架降低晚期血栓但永久性植入致极晚期失败风险。
核心结论
- 当前介入心脏病学中,支架血栓、再狭窄和出血之间的权衡是复杂挑战,需综合优化支架技术和抗血小板治疗。
研究设计与样本
- 综述文章,回顾介入心脏病学40年演进,聚焦支架技术和抗血小板治疗的进展。
主要发现
- 第一代药物洗脱支架显著降低再狭窄率,但以增加晚期支架血栓为代价。
- 延长抗血栓治疗降低支架血栓率,但增加出血风险。
- 第二代药物洗脱支架降低晚期支架血栓发生率,但永久性植入妨碍血管结构与功能完全恢复,伴极晚期支架失败风险。
临床怎么用
- 临床需在支架血栓、再狭窄和出血风险间个体化权衡,关注支架技术及抗血小板治疗进展以改善冠心病患者管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The field of interventional cardiology has significantly evolved over 40 years by overcoming several challenges. The introduction of first-generation drug-eluting stents significantly reduced the rates of restenosis, but at the expense of an increase of late stent thrombosis. Prolonged antithrombotic therapy reduced rates of stent thrombosis, but at the cost of increased bleeding. Although the advent of second-generation drug-eluting stents subsequently reduced the incidence of late stent thrombosis, its permanent nature prevents full recovery of vascular structure and function with accordant risk of very late stent failure. In the present era of interventional cardiology, the tradeoff between stent thrombosis, restenosis, and bleeding presents as a particularly complex challenge. In this review, the authors highlight major contributors of late/very late stent thrombosis while targeting stent restenosis, and they discuss evolutionary advances in stent technology and antiplatelet therapy, to further improve upon the care of patients with coronary artery disease.
引用
- Torrado J, Buckley L, Durán A, et al. Restenosis, Stent Thrombosis, and Bleeding Complications: Navigating Between Scylla and Charybdis. J Am Coll Cardiol. 2018. PMID: 29650125. doi:10.1016/j.jacc.2018.02.023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。